First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...

The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated ...

Metabolic associated fatty liver disease (MAFLD) is one of the most prevalent chronic liver diseases, with a rising incidence worldwide. In 2024, The ...

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, into Phase III trials for treating MASH ...

In 2024, The Food and Drug Administration in the US approved resmetirom, a liver-targeted thyroid hormone receptor ...

Risk for bleeding is higher among patients with cirrhosis who undergo colorectal endoscopic mucosal resection.

Discover a new model predicting liver cancer risk in hepatitis B patients without cirrhosis. It identifies a nonlinear link ...

Detailed price information for Akero Therapeutics Inc (AKRO-Q) from The Globe and Mail including charting and trades.

Attempts to obtain more lasting relief from ascites have been many and varied. In 1896 Drummond and Morison 1 reported the first surgical treatment of ascites. Talma, 2 in 1898, is usually ...

Detailed price information for Galectin Therapeutic (GALT-Q) from The Globe and Mail including charting and trades.

It affects around 60 per cent of people with cirrhosis within 10 years of their diagnosis, and the two-year survival rate is 50 percent. Causes Cirrhotic ascites develop when blood pressure in the ...

The REVEAL-II (Risk Evaluation of Viral Load Elevation and Associated Liver Diseases) clinical cohort has been described (23). Briefly, treatment-naive HCV+ patients without HCC were enrolled in the ...